Smoothing T cell roads to the tumor: Chemokine post-translational regulation

Area of Science:

• Immunology
• Oncology
• Biochemistry

Background:

• Tumor cells create an immunosuppressive microenvironment, hindering anti-cancer immune responses.
• Post-translational modifications of chemokines by reactive nitrogen species (RNS) are a novel immunosuppressive mechanism.
• This mechanism contributes to immune evasion in various cancers.

Purpose of the Study:

• To elucidate the novel tumor-associated immunosuppressive mechanism involving RNS.
• To develop a therapeutic agent, AT38, to counteract RNS-mediated immunosuppression.
• To evaluate the potential of AT38 in combination with cancer immunotherapy.

Main Methods:

• Investigated chemokine modifications by RNS in the tumor microenvironment.
• Designed and synthesized AT38, a novel RNS inhibitor.
• Assessed the efficacy of AT38 alone and in combination with immunotherapy in preclinical cancer models.

Main Results:

• Demonstrated that RNS post-translational modifications of chemokines suppress anti-tumor immunity.
• AT38 effectively inhibited RNS generation at the tumor site.
• Combinatorial therapy with AT38 significantly enhanced the effectiveness of cancer immunotherapy protocols, leading to improved tumor control.

Conclusions:

• Identified a novel RNS-dependent immunosuppressive mechanism in cancer.
• AT38 represents a promising therapeutic strategy to overcome tumor-induced immunosuppression.
• Combining AT38 with immunotherapy offers a potent approach to boost anti-cancer immune responses.